Organon & Co
OGN7.185USD
+0.095+1.34%
Fechamento 12/26, 16:00（ET）Cotações atrasadas em 15 min
1.87BValor de mercado
3.72P/L TTM
Mais detalhes de Organon & Co Empresa
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Informações de Organon & Co
Código da empresaOGN
Nome da EmpresaOrganon & Co
Data de listagemMay 14, 2021
CEOMorrissey (Joseph T)
Número de funcionários10000
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 14
Endereço30 Hudson Street
CidadeJERSEY CITY
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal07302
Telefone15514306000
Sitehttps://www.organon.com/
Código da empresaOGN
Data de listagemMay 14, 2021
CEOMorrissey (Joseph T)
Executivos da empresa Organon & Co
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Lead Independent Director
Lead Independent Director
--
--
Ms. Grace M. Puma Whiteford
Ms. Grace M. Puma Whiteford
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Women’s Health
462.00M
28.98%
Cardiovascular
283.00M
17.75%
Non-Opioid Pain, Bone and Dermatology
250.00M
15.68%
Respiratory
220.00M
13.80%
Other
206.00M
12.92%
Biosimilars
173.00M
10.85%
Por RegiãoUSD
Nome
Receita
Proporção
Europe and Canada
419.00M
26.29%
United States
414.00M
25.97%
Latin America, Middle East, Russia and Africa
285.00M
17.88%
Asia Pacific and Japan
250.00M
15.68%
China
204.00M
12.80%
Other
22.00M
1.38%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Women’s Health
462.00M
28.98%
Cardiovascular
283.00M
17.75%
Non-Opioid Pain, Bone and Dermatology
250.00M
15.68%
Respiratory
220.00M
13.80%
Other
206.00M
12.92%
Biosimilars
173.00M
10.85%
Distribuição de ações
Atualizado em: dom, 16 de nov
Atualizado em: dom, 16 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
13.76%
BlackRock Institutional Trust Company, N.A.
10.68%
MFS Investment Management
3.63%
State Street Investment Management (US)
3.59%
LSV Asset Management
3.01%
Outro
65.33%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
13.76%
BlackRock Institutional Trust Company, N.A.
10.68%
MFS Investment Management
3.63%
State Street Investment Management (US)
3.59%
LSV Asset Management
3.01%
Outro
65.33%
Tipos de investidores
Investidores
Proporção
Investment Advisor
47.62%
Investment Advisor/Hedge Fund
20.77%
Hedge Fund
4.75%
Pension Fund
2.56%
Research Firm
2.06%
Bank and Trust
0.92%
Sovereign Wealth Fund
0.86%
Individual Investor
0.36%
Venture Capital
0.04%
Outro
20.06%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
1485
219.88M
84.58%
-37.41M
2025Q2
1527
205.34M
78.98%
-50.49M
2025Q1
1611
213.21M
82.04%
-52.34M
2024Q4
1647
218.39M
84.67%
-40.43M
2024Q3
1625
211.80M
82.26%
-47.57M
2024Q2
1676
208.67M
81.14%
-51.47M
2024Q1
1700
205.29M
80.30%
-45.21M
2023Q4
1767
202.90M
79.38%
-24.07M
2023Q3
1835
205.61M
80.45%
-25.35M
2023Q2
2016
205.94M
80.75%
-21.55M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
32.15M
12.37%
+2.54M
+8.57%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
28.28M
10.88%
-627.34K
-2.17%
Jun 30, 2025
MFS Investment Management
10.11M
3.89%
-469.39K
-4.44%
Jun 30, 2025
State Street Investment Management (US)
9.52M
3.66%
+540.48K
+6.02%
Jun 30, 2025
LSV Asset Management
7.99M
3.07%
+8.69K
+0.11%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.40M
1.69%
-121.50K
-2.69%
Jun 30, 2025
Millennium Management LLC
9.09M
3.5%
+8.11M
+829.74%
Jun 30, 2025
AQR Capital Management, LLC
3.25M
1.25%
+1.88M
+136.10%
Jun 30, 2025
Gotham Asset Management, LLC
2.71M
1.04%
+1.31M
+93.22%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.63M
1.78%
+459.24K
+11.02%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
State Street SPDR S&P Pharmaceuticals ETF
1.72%
Alger Russell Innovation ETF
1.39%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.22%
First Trust Health Care Alphadex Fund
1.1%
Invesco S&P SmallCap Health Care ETF
1.07%
Brandes US Small-Mid Cap Value ETF
1.05%
iShares U.S. Pharmaceuticals ETF
0.65%
Lattice Hartford Multifactor Small Cap ETF
0.5%
WisdomTree U.S. SmallCap Dividend Fund
0.5%
Royce Quant Small-Cap Quality Value ETF
0.45%
Ver Mais
State Street SPDR S&P Pharmaceuticals ETF
Proporção1.72%
Alger Russell Innovation ETF
Proporção1.39%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.22%
First Trust Health Care Alphadex Fund
Proporção1.1%
Invesco S&P SmallCap Health Care ETF
Proporção1.07%
Brandes US Small-Mid Cap Value ETF
Proporção1.05%
iShares U.S. Pharmaceuticals ETF
Proporção0.65%
Lattice Hartford Multifactor Small Cap ETF
Proporção0.5%
WisdomTree U.S. SmallCap Dividend Fund
Proporção0.5%
Royce Quant Small-Cap Quality Value ETF
Proporção0.45%
Dividendo
Um total de
1.03B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Nov 10, 2025
OGN.NB Final Cash Dividend of gross USD 0.02 paid on Dec 11, 2025 going ex on Nov 20, 2025
Nov 20, 2025
Dec 11, 2025
Nov 20, 2025
Aug 05, 2025
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Sep 11, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 11, 2025
Aug 15, 2025
May 01, 2025
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Jun 12, 2025 going ex on May 12, 2025
May 12, 2025
Jun 12, 2025
May 12, 2025
Feb 13, 2025
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 13, 2025 going ex on Feb 24, 2025
Feb 24, 2025
Mar 13, 2025
Feb 24, 2025
Oct 31, 2024
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 12, 2024 going ex on Nov 12, 2024
Nov 12, 2024
Dec 12, 2024
Nov 12, 2024
Aug 06, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 12, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 12, 2024
Aug 16, 2024
May 02, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 13, 2024 going ex on May 10, 2024
May 13, 2024
Jun 13, 2024
May 10, 2024
Feb 15, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 14, 2024 going ex on Feb 23, 2024
Feb 26, 2024
Mar 14, 2024
Feb 23, 2024
Nov 02, 2023
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 14, 2023 going ex on Nov 10, 2023
Nov 13, 2023
Dec 14, 2023
Nov 10, 2023
Aug 08, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 14, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 14, 2023
Aug 17, 2023
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
Perguntas frequentes
Quem são os cinco principais acionistas de Organon & Co?
Os cinco principais acionistas de Organon & Co são:
The Vanguard Group, Inc. detém 32.15M Ações, representando 12.37% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 28.28M Ações, representando 10.88% do total de Ações.
MFS Investment Management detém 10.11M Ações, representando 3.89% do total de Ações.
State Street Investment Management (US) detém 9.52M Ações, representando 3.66% do total de Ações.
LSV Asset Management detém 7.99M Ações, representando 3.07% do total de Ações.
The Vanguard Group, Inc. detém 32.15M Ações, representando 12.37% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 28.28M Ações, representando 10.88% do total de Ações.
MFS Investment Management detém 10.11M Ações, representando 3.89% do total de Ações.
State Street Investment Management (US) detém 9.52M Ações, representando 3.66% do total de Ações.
LSV Asset Management detém 7.99M Ações, representando 3.07% do total de Ações.
Quais são os três principais tipos de acionistas de Organon & Co?
Os três principais tipos de acionistas da Organon & Co são:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
MFS Investment Management
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
MFS Investment Management
Quantas instituições possuem ações da Organon & Co (OGN)?
Em 2025Q3, 1485 instituições possuíam ações da Organon & Co, com valor de mercado aproximado de 219.88M, representando 84.58% do total de ações. Em comparação com 2025Q2, a participação institucional aumentou em 5.59%.
Qual é a maior fonte de receita da Organon & Co?
Em FY2025Q2, o segmento de negócios Women’s Health gerou a maior receita para Organon & Co, totalizando 462.00M e representando 28.98% da receita total.
